Coree Announces World's First Identification of Unique Microbiome Biomarkers in Diabetes and Obesity Patients

From the left, Dr. Marinaeli Park, CEO Sungjun Han, Dr. Mateo Scenu, Chairman Jongyun Lim, Professor Lorenza Putignani, Professor Daehui Kang, Professor Intaek Lim. Provided by DXVX

Coree announced on September 15 that it has become the first in the world to present analysis results of unique biomarkers in the microbiomes of diabetes and obesity patients.

From September 11 to 13, Coree presented its findings on the distinctive microbial distribution in obese and diabetic patients at the 38th Annual Workshop of the European Helicobacter & Microbiota Study Group (EHMSG), held in Rome, Italy. EHMSG is a globally renowned academic society with a tradition spanning over 30 years, and this year’s event brought together more than 500 researchers and clinicians from around the world.

This year, Coree participated as an official sponsor of the conference. Members of the Future Medical Innovation Research Association, including Chairman Jongyun Lim of Coree, CEO Sungjun Han of Coree, Professor Daehui Kang of Seoul National University, and Professor Intaek Lim of Catholic University, as well as over 30 scientists from Korea, attended and actively engaged in academic exchanges.

The highlight of the conference was a joint research presentation by Professor Lorenza Putignani (clinical microbiologist at Sapienza University of Rome and Gemelli Hospital, IRCCS Bambino Gesu Children's Hospital). This clinical study, jointly conducted by researchers from Gemelli Hospital, Coree and Coree Pohang, and Catholic University of Italy, analyzed samples from 93 patients with obesity and type 2 diabetes and 45 healthy controls. As a result, the team was the first in the world to identify patient-specific characteristics in microbiome distribution.

The joint study involved metagenomic analysis of stool and saliva samples from patients. The results showed a marked decrease in gut microbial diversity in the obese patient group compared to the healthy control group. In particular, specific bacterial groups such as Clostridium_Q and CAG-74 were proposed as potential biomarkers, indicating their possible use as indicators to distinguish between groups of obese and diabetic patients. Additionally, in the case of type 2 diabetes patients, differences were observed in the oral microbiome, with Parvimonas and Aggregatibacter being identified as potential biomarkers.

Sungjun Han, CEO of Coree, stated, “These unique biomarker results are the first in the world to statistically identify significant microbiome distribution characteristics in diabetes and obesity patients. Through further research, these findings could lead to the development of biomarkers useful for early diagnosis and prediction of treatment response.”

Professor Daehui Kang of the Department of Preventive Medicine at Seoul National University College of Medicine said, “This research achievement serves as a great inspiration to global researchers, including those in Korea. It demonstrates the potential for Helicobacter and microbiome research to expand into new therapeutic paradigms.”

This research is significant not only as a discovery but also as a foundation for future diagnostic platforms, new drug development, and fecal microbiota transplantation (FMT). Through this announcement, Coree has presented a clear roadmap for the development of diagnostics, therapeutics, and FMT as future growth drivers.

EHMSG is a prestigious international academic platform that has continued for over 30 years, sharing the latest research on Helicobacter pylori and gut microbiota each year. With the Coree-Gemelli collaborative research drawing attention at this year’s Rome workshop, it is expected that Korean companies and researchers will further strengthen their presence on the global academic stage.